Panama is set to become the first country in Central America to legalise and regulate medicinal cannabis after the 44-member National Assembly voted unanimously in favour of doing so.
Originally presented in 2019, Bill 153 creates a regulatory framework that will allow Panamanians with epilepsy, multiple sclerosis, cancer, glaucoma, arthritis and other chronic degenerative illnesses and pain to register to access medicinal cannabis.
This article was written by one of CannIntelligence’s international correspondents. We currently employ more than 40 reporters around the world to cover individual cannabis and cannabinoid markets. For a full list, please see our Who We Are page.
Our Key Benefits
The global cannabis market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.
CannIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.
Stay informed of any legal and market change in the sector that impacts your organisation
Maximise resources by getting market and legal data analysis daily in one place
Make smart decisions by understanding how the regulatory and market landscape evolves
Anticipate risks in your decisions by monitoring regulatory changes that impact your organization
Thanks for getting in touch with us
Please leave your enquiry and we will get back to you within 24 hours
LATEST ALERTS
